Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03662659 · ClinicalTrials.gov registry record · Phase 2

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

A Phase 2 study of Gastric Cancer and Esophagogastric Junction, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
274
Enrollment target
20
Study locations

NCT03662659 is a Phase 2 study of Gastric Cancer and Esophagogastric Junction that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 274 participants, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03662659, a Phase 2 study of Gastric Cancer and Esophagogastric Junction, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
274 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

Conditions Studied

Gastric Cancer Esophagogastric Junction Cancer of the Stomach

Interventions

  • BIOLOGICAL Nivolumab
  • DRUG FOLFOX
  • DRUG XELOX
  • DRUG SOX
  • BIOLOGICAL BMS-986213

Study Locations (20)

California

  • Local Institution - 0049 - Clovis
  • Local Institution - 0064 - Duarte
  • Scripps Clinic - La Jolla
  • Local Institution - 0040 - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach
  • Local Institution - 0041 - Orange
  • Local Institution - 0077 - Santa Monica

Colorado

  • Local Institution - 0056 - Aurora

Connecticut

  • Local Institution - 0062 - New Haven

New Jersey

  • Local Institution - 0050 - Hackensack

Texas

  • Local Institution - 0054 - Dallas

Virginia

  • Virginia Cancer Institute - Richmond

Washington

  • Local Institution - 0052 - Seattle

Buenos Aires

  • Local Institution - 0010 - Ciudad Autónoma de Buenos Aires

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2018-10-16
Est. Completion 2024-01-18
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03662659

The ClinicalTrials.gov registry entry for NCT03662659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (14% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.

NCT03662659 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03662659 about?

NCT03662659 is a clinical study titled "An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers". The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

What is the current status of trial NCT03662659?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2018-10-16. Estimated completion is 2024-01-18.

What conditions does trial NCT03662659 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophagogastric Junction, Cancer of the Stomach.

What interventions are being tested in trial NCT03662659?

The interventions under investigation include: Nivolumab (BIOLOGICAL), FOLFOX (DRUG), XELOX (DRUG), SOX (DRUG), BMS-986213 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03662659?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03662659 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Esophagogastric Junction

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.